Mergers & Acquisitions

Irrimax Acquired by ARCHIMED

5859 Irrimax NT SP

M&A Engagement Overview

Industry Group: Healthcare & Life Sciences
Areas of Focus: Medical Products and Devices; Medical and Surgical Equipment 

Infection control is one of the toughest challenges for hospitals to solve, and surgical site infections generate billions of dollars in incremental costs for the U.S. healthcare system on an annual basis. The market for high-efficacy surgical and post-surgical wound irrigation is expected to grow significantly in the medium-term as the financial burden on hospitals provides incentives to implement strict protocols to manage hospital acquired infections. ARCHIMED has a clear appreciation for the full potential of Irrimax’s products and will be an excellent partner to the company as they enter their next phase of growth.

Harris Williams advised Irrimax on their sale to ARCHIMED, a private equity healthcare specialist with offices in Europe, North America, and Asia. Irrimax is a global market leader in antimicrobial wound cleansing and develops and markets Irrisept®, the market leading solution for antimicrobial wound lavage.

Irrimax’s clinically differentiated products are recognized for their safety, efficacy, and ease of use. The company’s reputation in the market, strong intellectual property portfolio, and robust clinical evidence supporting the efficacy and safety of their products provided a compelling investment opportunity for ARCHIMED.

ARCHIMED has significant expertise in surgical and operating consumables and wound care, and the partnership between the two companies will help Irrimax expand their product range, markets, and global reach.  

Contact the Harris Williams Healthcare & Life Sciences Group to learn more about this client engagement.